<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------------
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND
15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.
000-23328
-------------------------------------------------------------------------------
COMMISSION FILE NUMBER
DEOTEXIS, INC.
-------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
885 THIRD AVENUE, SUITE 2900, NEW YORK, NEW YORK 10022-4834
-------------------------------------------------------------------------------
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
COMMON STOCK, PAR VALUE $.001
-------------------------------------------------------------------------------
(TITLE OF EACH CLASS OF SECURITIES COVERED BY THIS FORM)
N/A
-------------------------------------------------------------------------------
(TITLES OF ALL OTHER CLASSES OF SECURITIES FOR WHICH A DUTY TO FILE REPORTS
UNDER SECTION 13(A) OR 15(D) REMAINS)
Please place an X in the box(es) to designate the appropriate rule provision(s)
relied upon to terminate or suspend the duty to file reports:
-------------------------------------------------------------------------------
Rule 12g-4(a)(1)(i) |X| Rule 12h-3(b)(1)(ii) |_|
Rule 12g-4(a)(1)(ii) |_| Rule 12h-3(b)(2)(i) |_|
Rule 12g-4(a)(2)(i) |_| Rule 12h-3(b)(2)(ii) |_|
Rule 12g-4(a)(2)(ii) |_| Rule 15d-6 |_|
Rule 12h-3(b)(1)(i) |X|
Approximate number of holders of record as of the certification or notice date:
169
-------------------------------------------------------------------------------
Pursuant to the requirements of the Securities Exchange Act of 1934,
Deotexis, Inc. has caused this certification/notice to be signed on its behalf
by the undersigned duly authorized person.
Date: November 10, 2000 By: /s/ ROBERT B. LACHENAUER
-------------------------
ROBERT B. LACHENAUER
ASSISTANT SECRETARY
<PAGE>
TO THE STOCKHOLDERS OF DEOTEXIS, INC.
November 10, 2000
Dear Stockholder,
As you know, Deotexis, Inc. (the "Company") has been listed on the NASDAQ
Bulletin Board and the Bermuda Stock Exchange (BSX) for several years, in
anticipation of the day when the Company's business would become established in
the United States. The Company's entry into the U.S. market has not yet taken
place, largely due to the high levels of interest that the Deotexis technology
has generated in Europe, which continues to require all the Company's
resources.
In order to pursue developments in Europe, it has become increasingly clear to
your management that, for the immediate future, the Company's resources need to
be fully concentrated on that region. It is in Europe that discussions with
large potential licensees of the Deotexis technology are taking place, and
where the operations of the Company's German subsidiary, Deotexis-Hecking, are
being developed. It is also there that the Company is monitoring its investment
in Medisana AG.
In order to maximize its resources to concentrate on its European activities,
your management has therefore decided to reduce its presence in the United
States. This will also have the effect of cutting costs, particularly the cost
of professional fees, which remain a significant expenditure for a company in
the start-up phase. The steps management have taken include a significant
downsizing, including a filing to de-register the Company's common stock with
the SEC and de-list the stock on the NASDAQ and BSX.
Although the Company will no longer be listed on the BSX and NASDAQ, transfers
of its stock will continue to be administered post-filing by the Company's
present stock transfer agent, Continental Stock Transfer & Trust Company, New
York.
It is the Company's hope that once it has achieved the necessary level of
commercial operations in Europe, it will be able to re-list its shares on
either a European or a U.S. stock exchange. Your continued support in achieving
this goal is greatly appreciated.
Sincerely,
Gerold Tebbe
Chief Executive Officer
